Retatrutide vs CagriSema: Triple Agonist vs GLP-1/Amylin Combination

The Verdict

Retatrutide (Eli Lilly) is a triple agonist targeting GLP-1, GIP, and glucagon receptors, with Phase 2 data showing up to 24.2% weight loss at 48 weeks. CagriSema (Novo Nordisk) is a co-formulation of semaglutide (GLP-1 agonist) and cagrilintide (long-acting amylin analog) in a single weekly injection, with Phase 3 data from REDEFINE-1 showing approximately 22.7% weight loss at 68 weeks. These are arguably the two most anticipated next-generation weight loss treatments in development, representing two very different scientific strategies for surpassing current options. Retatrutide's approach targets metabolic expenditure through glucagon. CagriSema's approach layers amylin-driven satiety on top of GLP-1 therapy. Both show promise for patients who need weight loss beyond what currently approved medications deliver. Neither retatrutide is approved; CagriSema has submitted regulatory applications.

Quick Comparison

Mechanism of Action: Two Different Multi-Target Strategies

Retatrutide: The Expenditure Play

Retatrutide is a single peptide molecule that activates three receptors at once. GLP-1 suppresses appetite and enhances insulin secretion. GIP improves insulin sensitivity and optimizes fat metabolism. Glucagon increases resting energy expenditure, promotes liver fat oxidation, and raises basal metabolic rate.

The glucagon receptor is the distinguishing feature. It works on the output side of energy balance, essentially telling the body to burn more fuel. This counteracts the metabolic slowdown that normally accompanies weight loss and drives the aggressive liver fat clearance seen in retatrutide's trials.

CagriSema: The Satiety Play

CagriSema is not a single molecule but a co-formulation of two separate drugs in one injection. Semaglutide 2.4 mg (the same molecule in Wegovy) provides GLP-1 receptor agonism. Cagrilintide 2.4 mg is a long-acting amylin receptor agonist that provides a second, independent satiety signal.

Amylin is a hormone co-secreted with insulin from the pancreas. It acts on the area postrema and other brainstem regions to produce powerful feelings of fullness, slow gastric emptying, and suppress post-meal glucagon. When combined with GLP-1, the dual satiety effect is greater than either pathway alone. CagriSema essentially layers two different "stop eating" signals on top of each other.

Why This Distinction Matters

Retatrutide says: "Eat less and burn more." CagriSema says: "Eat much, much less." Both approaches produce significant weight loss, but they arrive there through different physiological pathways, and the secondary effects differ substantially.

Retatrutide's glucagon component produces liver fat oxidation, increased thermogenesis, and metabolic rate elevation. CagriSema's amylin component may produce more favorable body composition (better preservation of lean mass relative to fat mass), though this needs more data to confirm.

Weight Loss: TRIUMPH vs REDEFINE

Retatrutide: TRIUMPH Phase 2

The Phase 2 TRIUMPH trial enrolled 338 adults with obesity. Key results at the 12 mg dose:

• 24.2% average weight loss at 48 weeks
• Extended data reaching approximately 28.7% with no clear plateau
• 71% of participants lost 20%+ of body weight
• 54% lost 25%+

CagriSema: REDEFINE Phase 3

The REDEFINE-1 trial was larger and longer, as expected for a Phase 3 study. Key results:

• Approximately 22.7% average weight loss at 68 weeks
• About 53% of participants lost 20%+ of body weight
• About 34% lost 25%+
• CagriSema exceeded the weight loss of semaglutide alone (the comparator arm), confirming that cagrilintide adds meaningful efficacy on top of already-effective GLP-1 therapy

Reading Between the Numbers

The headline weight loss figures appear similar (24.2% vs 22.7%), but the timelines are very different. Retatrutide achieved its result at 48 weeks; CagriSema needed 68 weeks. This means retatrutide produced weight loss faster, and its extended data (28.7%) suggest the ultimate gap could be larger.

However, comparing Phase 2 data to Phase 3 data is inherently uncertain. Phase 2 trials are smaller and sometimes show higher efficacy than Phase 3. Until retatrutide's Phase 3 TRIUMPH data are available, we should hold the comparison somewhat loosely.

CagriSema's REDEFINE data have the advantage of being Phase 3. They come from a larger patient population, represent more rigorous study design, and are what Novo Nordisk has submitted for regulatory review. These numbers are the ones regulators are evaluating right now.

Body Composition

One of the most important questions in obesity pharmacology is not just how much weight a drug removes, but what kind of weight it removes. Losing muscle alongside fat can undermine long-term health and physical function.

CagriSema may have an advantage here. Amylin receptor agonism has shown early signals of preferentially promoting fat loss while relatively preserving lean mass. If confirmed in larger studies, this would be clinically meaningful. Losing 22% of body weight with good muscle preservation could produce better functional outcomes than losing 25% with significant muscle wasting.

Retatrutide's glucagon component increases energy expenditure, which could theoretically influence body composition by promoting fat oxidation specifically. However, detailed body composition data from the Phase 2 trial have not been extensively reported.

Both programs need to publish comprehensive DEXA or similar body composition analyses before we can make strong claims about which drug produces better quality weight loss. This is an area to watch closely as Phase 3 data emerge.

Liver Fat

Retatrutide has a decisive advantage in liver fat reduction. The glucagon receptor directly drives hepatic fat oxidation, producing approximately 82% median reduction in liver fat at 48 weeks. Nearly all participants with significant fatty liver at baseline normalized. Eli Lilly is pursuing MASLD/MASH as a separate indication for retatrutide.

CagriSema's liver fat data are less prominent. GLP-1 agonists do reduce liver fat (semaglutide is being studied for MASH separately), and amylin may contribute additional metabolic benefits. But without the glucagon receptor's direct hepatic fat oxidation effect, CagriSema is unlikely to match retatrutide's liver fat clearance.

For patients with MASLD/MASH as a significant comorbidity, retatrutide's liver data represent a meaningful differentiator.

Side Effects

Both drugs share GLP-1-mediated gastrointestinal side effects: nausea, vomiting, diarrhea, and constipation. These are most pronounced during dose titration.

CagriSema (REDEFINE-1)

GI adverse events were reported at rates consistent with high-dose semaglutide therapy. Nausea was the most common. The addition of cagrilintide did not appear to dramatically increase GI side effects beyond what is seen with semaglutide alone, which is encouraging. Discontinuation rates due to adverse events were in the expected range for the drug class.

Retatrutide (TRIUMPH Phase 2)

GI side effects occurred in approximately 40-50% of participants at higher doses. The glucagon receptor added a mild heart rate increase of 2-4 bpm, not seen with CagriSema. No adverse cardiovascular events were associated with this heart rate change in Phase 2.

The heart rate difference is notable. CagriSema, without a glucagon component, does not carry this effect. For patients with heart rate-sensitive conditions, this could influence the choice between the two drugs, though the clinical significance of a 2-4 bpm increase remains to be fully evaluated.

Who Should Consider Each

Retatrutide may be better suited for patients who:

• Have severe obesity requiring maximum weight loss
• Have significant fatty liver disease (MASLD/MASH)
• Want a single-molecule approach with the broadest receptor coverage
• Are willing to wait for Phase 3 results and FDA approval
• Prioritize metabolic rate enhancement alongside appetite suppression

CagriSema may be better suited for patients who:

• Want a next-generation option that may reach the market sooner
• Are concerned about lean mass preservation during weight loss
• Prefer a mechanism focused purely on appetite and satiety pathways
• Do not have significant liver disease as a primary concern
• Want a drug from Novo Nordisk, building on the proven semaglutide platform

Timeline and Regulatory Status

CagriSema is ahead in the regulatory process. Novo Nordisk has completed its Phase 3 REDEFINE program and submitted regulatory applications. If approved, CagriSema could reach the market in 2025 or 2026. This would make it one of the first next-generation obesity medications to become commercially available.

Retatrutide is in Phase 3 through the TRIUMPH program, with results expected over the coming year or two. Estimated FDA approval is late 2026 to 2027. Eli Lilly has the resources and infrastructure to support a large-scale launch, but retatrutide is likely to reach the market after CagriSema.

The competitive dynamic between Eli Lilly and Novo Nordisk is driving rapid innovation. Both companies are investing heavily in next-generation obesity treatments, and both have deep pipelines beyond these two drugs. Patients are the beneficiaries of this competition.

Frequently Asked Questions

Which drug produces more weight loss?

Based on currently available data, retatrutide's Phase 2 numbers (24.2% at 48 weeks, ~28.7% extended) are higher than CagriSema's Phase 3 numbers (22.7% at 68 weeks). However, comparing Phase 2 to Phase 3 data introduces uncertainty. We will need retatrutide's Phase 3 results for a fair comparison.

Is CagriSema just Wegovy plus an amylin drug?

Yes. CagriSema combines semaglutide 2.4 mg (the same active ingredient and dose as Wegovy) with cagrilintide 2.4 mg (a long-acting amylin analog) in a single weekly injection. The combination produces greater weight loss than semaglutide alone, validating the additional benefit of the amylin pathway.

Will I be able to switch from CagriSema to retatrutide?

If both drugs reach the market, switching would be a clinical decision between you and your physician. These drugs work through different receptor pathways, so the transition would need to be managed carefully. Specific switching protocols would be developed once both are available.

Could I use CagriSema now and switch to retatrutide later?

Neither drug is currently available for prescription. CagriSema may reach the market first based on its regulatory timeline. If it becomes available before retatrutide, starting CagriSema and potentially transitioning later would be a reasonable strategy to discuss with your physician.

Which drug is safer?

Both have acceptable safety profiles in their clinical programs. Retatrutide has a mild heart rate increase from the glucagon receptor that CagriSema does not share. CagriSema's side effect profile is broadly consistent with high-dose semaglutide. Larger Phase 3 trials and post-marketing surveillance will provide more definitive safety comparisons.

Our Perspective

Retatrutide and CagriSema represent two compelling answers to the question: "What comes after Wegovy and Zepbound?" Both deliver weight loss that approaches or exceeds bariatric surgery outcomes, which is remarkable for a weekly injection.

The choice between them will ultimately come down to individual patient factors. Patients with liver disease may lean toward retatrutide. Those concerned about muscle preservation may prefer CagriSema. Many patients will benefit from whichever reaches the market first.

While we watch these programs with genuine excitement, we want to be clear: effective treatment is available right now. Semaglutide and tirzepatide are producing significant results for our patients every day. If you are ready to start your weight management process, there is no reason to wait. Our clinical team at FormBlends is here to help you find the right physician-supervised treatment for your goals today.